Erythroid colony growth in the presence and absence of erythropoietin was compared in 23 patients with primary proliferative polycythaemia (PPP), nine with idiopathic erythrocytosis, 10 with secondary polycythaemia, 15 with pseudopolycythaemia and in 76 normal subjects. Erythroid colonies growing without erythropoietin stimulation (endogenous erythroid colonies) from peripheral blood (BFU-E) were found in 20 of 22 patients with PPP and in two of seven with idiopathic erythrocytosis. None was found in secondary polycythaemia, pseudopolycythaemia, or in normal subjects. Small numbers of endogenous colony forming units-erythroid (CFU-E) (though not BFU-E) were cultured from the bone marrow of three of 24 normal subjects, suggesting that peripheral blood cultures provide a more specific indicator of clonal erythropoiesis.
True erythrocytosis may be the result of increased concentrations of erythropoietin, caused-for example, by hypoxia or a renal carcinoma (secondary polycythaemia)-or it may be due to the clonal expansion of an abnormal haemopoietic stem cell which can also result in an increase in the numbers of leucocytes and platelets (primary proliferative polycythaemia) (PPP). Patients who do not meet the standard criteria for PPP' and who do not have a demonstrable cause for their erythrocytosis are grouped together as having idiopathic erythrocytosis. This is a heterogeneous group, some of whom may be in the early stages of PPP, and who go on to develop all the features of this disease. In 1974 Prchal et al reported that cultured marrow erythroid progenitors from patients with PPP formed colonies in vitro without the addition of erythropoietin-endogenous erythroid colonies (EEC).2 EEC were shown to be produced by the abnormal clone3 and have been found in other myeloproliferative disorders.45 As well as being used to distinguish PPP from secondary polycythaemia, particularly in cases where the standard criteria are not satisfied, 6 EEC have recently been used to identify a subgroup of patients with idiopathic erythrocytosis who have clonal disease and who may therefore be at greater risk of developing ppp.7 8 We compared peripheral blood with bone marrow cultures to detect EEC growth, because peripheral blood is more easily obtained. These studies were carried out in patients with true erythrocytosis (PPP, idiopathic erythrocytosis, secondary polycythaemia), those whose increased haematocrit was due to reduced plasma volume (pseudopolycythaemia),9 and in normal subjects to identify the different patterns of growth in clonal and non-clonal erythropoiesis. We also report the finding of EEC in four patients with iron deficiency who did not meet the criteria for PPP.
Methods
The clinical details of the patients and normal subjects included in this study are summarised in table 1. Most patients were studied at presentation and none had received any treatment other than venesection before testing.
PRIMARY PROLIFERATIVE POLYCYTHAEMIA
The criteria for this diagnosis were based on those suggested by the Polycythaemia Study CFU-E and BFU-E from normal subjects at 1-0 U/ml erythropoietin were calculated on logarithmically transformed data. Erythroid colony growth at 1-0 U/ml erythropoietin from patients and normal subjects was compared using the non-parametric Mann-Whitney U test. 
ENDOGENOUS ERYTHROID COLONIES IN BONE MARROW
A small number ofnormal subjects (three of24) grew low numbers of CFU-E, but not BFU-E, from their bone marrow without added erythropoietin. Endogenous CFU-E were observed from all 13 patients with PPP where bone marrow was available, including the two patients who did not grow EEC from their peripheral blood, and this is significantly different from normal (p < 0-001). Growth of endogenous BFU-E from bone marrow was less common in PPP (eight of 13 patients) than either endogenous CFU-E or peripheral blood BFU-E, but still significantly different from normal (p < 0 00 1). A significantly greater proportion of patients with idiopathic erythrocytosis (four of five) grew endogenous CFU-E than normal subjects In PPP, the addition of 10 U/ml erythropoietin to peripheral blood cultures resulted in increased numbers of BFU-E in all except one case, where the colonies were already too numerous for accurate counting (BFU-E without added erythropoietin:median 36, range 0-> 10 000/ ml; BFU-E with 10 U/ml erythropoietin:median 385, range 91-> 10 000/ml). This was significantly higher than the numbers of erythroid colonies produced by normal subjects at 1-0 U/ml erythropoietin (111, 21-436 BFU-E/ml), p < 0 0001. Peripheral blood BFU-E at 10 U/ml erythropoietin from patients with idiopathic erythrocytosis (median 241, range 146-499 BFU-E/ml) fell within the normal range as did those from patients with secondary polycythaemia (114, 24-365 BFU-E/ml) and pseudopolycythaemia (146, 35-437 BFU-E/ml).
The number of CFU-E at 10 U/ml erythropoietin was significantly higher in patients with PPP than in normal subjects (p = 0 023) (fig 2A) , although the range of results was similar (PPP, median 424, range 97-562 CFU-E/105 mononuclear cells; normal controls, median 163, range 84-557 CFU-E/105 mononuclear cells). The growth of CFU-E at 10 U/ml erythropoietin from patients with idiopathic erythrocytosis was not significantly different from that of normal controls.
In contrast to the peripheral blood results, bone marrow BFU-E at 0 U/ml erythropoietin from patients with PPP were not significantly increased compared with those of normal controls (fig 2B) , and those from patients with idiopathic erythrocytosis were also within the normal range.
Discussion
Patients with PPP are more likely to bleed or have thrombosis than patients with other forms of erythrocytosis,12 and it is therefore helpful to be able to identify those at risk at an early stage. Prchal et al showed that the marrow EEC found in PPP are products of the abnormal haemopoietic clone,3 and EEC have recently been increasingly used as a means of identifying true myeloproliferative disease in patients with erythrocytosis.' We investigated the feasibility of using EEC growth from peripheral blood, as this is more readily available than bone marrow samples, to distinguish clonal erythrocytosis from non-clonal disease on an individual basis in patients with erythrocytosis.
EEC have been reported in some normal peripheral blood samples"3 using serum free conditions and adherence-depleted cells, and as we were concerned with the specificity of this test we studied a large number of normal controls covering the same age range as our patients, but using culture conditions likely to reflect those pertaining in vivo. We found no evidence of EEC in normal peripheral blood, but a small proportion of normal subjects grew low numbers of endogenous CFU-E from bone marrow. In contrast, all the bone marrow samples from patients with PPP gave rise to endogenous CFU-E. A higher proportion of patients with idiopathic erythrocytosis (four of five) gave rise to endogenous CFU-E than normal, but the numbers were within the normal range and therefore could not be used to identify clonal disease with certainty in these patients. CFU-E are relatively mature erythroid progenitors and known to be the most sensitive to erythropoietin. " Therefore, the low numbers of endogenous CFU-E we observed in normal subjects probably either matured in response to the small amounts of erythropoietin present in the culture or had already been stimulated in vivo. Endogenous bone marrow BFU-E were observed in only eight of 13 (61-5%) patients with PPP and no patients with idiopathic erythrocytosis or normal subjects. In contrast, endogenous peripheral blood BFU-E were cultured from 20 of 22 (91 %) of patients with PPP and two of seven (29%) of patients with idiopathic erythrocytosis, and as we detected no EEC in blood from patients with secondary polycythaemia or pseudopolycythaemia or from normal subjects, circulating BFU-E seem more useful for detecting myeloproliferative disease in patients than bone marrow EEC under these culture conditions. This may be of particular relevance when the strict criteria for PPP are not met,'5 as for example where this is complicated by iron deficiency and the red cell volume may not exceed 125% of normal, or in idiopathic erythrocytosis, a heterogeneous condition, where the presence of endogenous peripheral blood BFU-E may help identify the subgroup at greatest risk of developing Ppp. '6 Why a higher proportion of patients with PPP should grow endogenous BFU-E from peripheral blood is not clear. These results may reflect a different balance of stimulatory and inhibitory accessory cells in the two sources of mononuclear cells,'7 18 some of which may themselves be products of the abnormal clone. De Wolf et al examined the effects of recombinant interleukin-3 (IL-3) and granulocytemacrophage colony-stimulating factor (GM-CSF) on peripheral blood EEC from patients with PPP and found that whereas IL-3 enhanced EEC growth from mononuclear cells and adherence-depleted mononuclear cells, GM-CSF only had an enhancing effect when the adherent cells were removed. ' 
